SOLIAIR

SoliAir Biosciences is a biotechnology company developing a new class of inhaled therapies to prevent and treat respiratory viral infections. The company's core technology, known as muco-trapping, involves engineering antibodies that bind to pathogens and tether them to the airway mucus layer, facilitating their rapid clearance through natural processes. This approach aims to provide a broad-spectrum, site-specific defense that can be administered via a simple inhaler or nasal spray. SoliAir's lead programs target major respiratory threats, including SARS-CoV-2 and Respiratory Syncytial Virus (RSV). By reinforcing the body's natural mucosal barrier, the company seeks to offer immediate protection and reduce the severity of airborne diseases. SoliAir was founded by leading researchers from Johns Hopkins University and is headquartered in Baltimore, Maryland.